[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
作者信息
Kondo Tsunenori
出版信息
Nihon Jinzo Gakkai Shi. 2012;54(5):574-80.
PMID:22991835
Abstract
摘要
相似文献
1
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].[血管内皮生长因子受体酪氨酸激酶抑制剂在肾细胞癌治疗中的作用]
Nihon Jinzo Gakkai Shi. 2012;54(5):574-80.
2
Two new drugs for renal cell carcinoma.两种用于治疗肾细胞癌的新药。
Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20.
3
[New drugs; sunitinib and sorafenib].[新药；舒尼替尼和索拉非尼]
Ned Tijdschr Geneeskd. 2007 Dec 29;151(52):2888-90.
4
New therapeutic options for renal cell carcinoma.肾细胞癌的新治疗选择。
Clin Adv Hematol Oncol. 2006 Jun;4(6):429-30.
5
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].德国多靶点酪氨酸激酶抑制剂获批上市后转移性肾细胞癌的医学治疗
Aktuelle Urol. 2009 Jan;40(1):31-6. doi: 10.1055/s-2008-1038176. Epub 2009 Jan 28.
6
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.晚期肾细胞癌中的酪氨酸激酶抑制剂：不断演变的治疗模式。
Clin Genitourin Cancer. 2009 Jan;7(1):9-10. doi: 10.3816/CGC.2009.n.001.
7
Renal-cell carcinoma--molecular pathways and therapies.肾细胞癌——分子途径与治疗方法
N Engl J Med. 2007 Jan 11;356(2):185-7. doi: 10.1056/NEJMe068263.
8
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.舒尼替尼和索拉非尼抗血管生成治疗期间出血性直肠结肠炎急性加重
Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. Epub 2008 Aug 22.
9
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.舒尼替尼、索拉非尼及mTOR抑制剂在肾癌中的应用
J BUON. 2007 Sep;12 Suppl 1:S151-62.
10
Kidney cancer: Does hypothyroidism predict clinical outcome?肾癌：甲状腺功能减退症能否预测临床结局？
Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30.
Zotero 插件